Top Markets
#1 QuantixAI QuantixAI +33.28%
#2 Siren Siren +31.57%
#3 MowCat MowCat +27.77%
#4 Prom Prom +26.57%
#5 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +24.85%
#6 Tutorial Tutorial +20.89%
#7 UnifAI Network UnifAI Network +19.01%
#8 Wrapped STX (Velar) Wrapped STX (Velar) +17.93%
#9 Versatize Coin Versatize Coin +16.67%
#10 Pons Pons +15.57%
Coin of the day
QuantixAI QuantixAI
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
ZIOPHARM Oncology, Inc. ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc.

ZIOP
Kedudukan dalam Saham #20769
ZIOPHARM Oncology, Inc. is a clinical-stage biopharmaceutical firm dedicated to... ZIOPHARM Oncology, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing innovative immuno-oncology treatments for cancer patients. The company leverages its proprietary Sleeping Beauty platform, which employs non-viral genetic engineering to modify T-cells outside the body using a transposon/transposase system for subsequent infusion. Additionally, ZIOPHARM is advancing its Controlled IL-12 technology, designed to precisely regulate the expression of interleukin-12 (IL-12), a key immune system regulator, to direct the patient's immune response against cancer cells. Its pipeline features several promising therapeutic candidates, including T-cell receptor (TCR) plus T-cell therapies aimed at solid tumors, chimeric antigen receptor (CAR) T-cell therapies specifically targeting CD19 for hematologic malignancies, and Ad-RTS-hIL-12 combined with veledimex, a gene delivery system for controlled IL-12 production under investigation for treating recurrent adult glioblastoma multiforme. ZIOPHARM maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., and research and development agreements, alongside patent licensing, with institutions such as The University of Texas MD Anderson Cancer Center and the National Cancer Institute. The company's headquarters are located in Boston, Massachusetts.
Harga Saham
$0.8657
Disegerakkan terakhir: 2022-01-26
Modal Pasaran
$122.22M
Perubahan (1 hari)
-0.88%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan ZIOPHARM Oncology, Inc. (ZIOP)

Kategori

Healthcare
Pendapatan untuk ZIOPHARM Oncology, Inc. (ZIOP)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini ZIOPHARM Oncology, Inc., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi ZIOPHARM Oncology, Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH